The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma

Autor: Cheng, Zhao, Mirza, Hasan, Ennis, Darren P, Smith, Philip, Morrill Gavarró, Lena, Sokota, Chishimba, Giannone, Gaia, Goranova, Theodora, Bradley, Thomas, Piskorz, Anna, Lockley, Michelle, BriTROC-1 Investigators, Kaur, Baljeet, Singh, Naveena, Tookman, Laura A, Krell, Jonathan, McDermott, Jacqueline, Macintyre, Geoffrey, Markowetz, Florian, Brenton, James D, McNeish, Iain A

PURPOSE: Ovarian high-grade serous carcinoma (HGSC) is usually diagnosed at late stage. We investigated whether late-stage HGSC has unique genomic characteristics consistent with acquisition of evolutionary advantage compared with early-stage tumors.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dc45d102dd91629eae1b3874958471a
https://www.repository.cam.ac.uk/handle/1810/332946

The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.

Autor: Cheng Z; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom., Mirza H; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom., Ennis DP; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom., Smith P; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom., Morrill Gavarró L; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom., Sokota C; Department of Cellular Pathology, Imperial College Healthcare NHS Trust, London, United Kingdom., Giannone G; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom.; Department of Oncology, University of Turin, Turin, Italy., Goranova T; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom., Bradley T; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom., Piskorz A; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom., Lockley M; Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Kaur B; Department of Cellular Pathology, Imperial College Healthcare NHS Trust, London, United Kingdom., Singh N; Department of Pathology, Barts Healthcare NHS Trust, London, United Kingdom., Tookman LA; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom., Krell J; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom., McDermott J; Department of Pathology, University College London Hospital NHS Trust, London, United Kingdom., Macintyre G; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom., Markowetz F; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom., Brenton JD; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom., McNeish IA; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Jul 01; Vol. 28 (13), pp. 2911-2922.